Search

Your search keyword '"Specker, Christof"' showing total 107 results
Start Over Author "Specker, Christof" Search Limiters Peer Reviewed
107 results on '"Specker, Christof"'

2. Befragung zu den Arbeits-, Weiterbildungs- und Forschungsbedingungen von Assistenzärztinnen und -ärzten in der internistisch-rheumatologischen Weiterbildung – BEWUSST

Author

Proft, Fabian, Vossen, Diana, Baraliakos, Xenofon, Berliner, Michael N., Fleck, Martin, Keyßer, Gernot, Krause, Andreas, Lorenz, Hanns-Martin, Manger, Bernhard, Schuch, Florian, Specker, Christof, Wollenhaupt, Jürgen, Voormann, Anna, Raspe, Matthias, Krusche, Martin, and Pfeil, Alexander

Published
2024
Full Text
View/download PDF

4. Rheumatologische Weiterbildungsstellen in Deutschland

Author

Pfeil, Alexander, Krusche, Martin, Proft, Fabian, Vossen, Diana, Braun, Jürgen, Baraliakos, Xenofon, Berliner, Michael N., Keyßer, Gernot, Krause, Andreas, Lorenz, Hanns-Martin, Manger, Bernhard, Schuch, Florian, Specker, Christof, Wollenhaupt, Jürgen, Voormann, Anna, and Fleck, Martin

Published
2023
Full Text
View/download PDF

5. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry

Author

Yazdany, Jinoos, Ware, Anna, Wallace, Zachary S., Bhana, Suleman, Grainger, Rebecca, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Hausmann, Jonathan S., Liew, Jean W., Sirotich, Emily, Jacobsohn, Lindsay, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson‐Tovey, Saskia, Kearsley‐Fleet, Lianne, Schaefer, Martin, Ribeiro, Sandra Lucia Euzebio, Al‐Emadi, Samar, Hasseli, Rebecca, Müller‐Ladner, Ulf, Specker, Christof, Schulze‐Koops, Hendrik, Bernardes, Miguel, Fraga, Vanessa Machado, Rodrigues, Ana Maria, Sparks, Jeffrey A., Ljung, Lotta, Di Giuseppe, Daniela, Tidblad, Liselotte, Wise, Leanna, Duarte‐García, Alí, Ugarte‐Gil, Manuel F., Colunga‐Pedraza, Iris Jazmín, Martínez‐Martínez, Marco Ulises, Alpizar‐Rodriguez, Deshire, Xavier, Ricardo Machado, Isnardi, Carolina A., Pera, Mariana, Pons‐Estel, Guillermo, Izadi, Zara, Gianfrancesco, Milena A., Carrara, Greta, Scirè, Carlo Alberto, Zanetti, Anna, and Machado, Pedro M.

Published
2024
Full Text
View/download PDF

6. Kriterien für die Weiterbildungsbefugnis zur Facharztkompetenz Innere Medizin und Rheumatologie – ein Positionspapier der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie.

Author

Pfeil, Alexander, Fleck, Martin, Aringer, Martin, Baraliakos, Xenofon, Ernst, Diana, Haase, Isabell, Hillebrecht, Christiana, Hoyer, Bimba Franziska, Keyßer, Gernot, Kötter, Ina, Krause, Andreas, Krusche, Martin, Lorenz, Hanns-Martin, Proft, Fabian, Schuch, Florian, Vossen, Diana, Voormann, Anna, Wagner, Ulf, Wollenhaupt, Jürgen, and Specker, Christof

Abstract

Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2025
Full Text
View/download PDF

9. Die Deutsche Gesellschaft für Rheumatologie und Klinische Immunologie e. V. (DGRh) und die COVID-19-Pandemie.

Author

Voormann, Anna Julia and Specker, Christof

Abstract

Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

10. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Author

Constantin, Arnaud, Gottenberg, Jacques Eric, Loiseau-Peres, Sylvie, Nguyen, Minh, Schaeverbeke, Thierry, Alten, Rieke H.-E., Amberger, Christopher, Biewer, Werner A., Boche, Konrad, Burmester, Gerd Ruediger, Engel, Andreas, Feuchtenberger, Martin, Fleck, Martin, Gauler, Georg, Heilig, Bernhard, Höhle, Maria, Iking-Konert, Christof, Kästner, Peter, Kofler, David, Krueger, Klaus, Kühne, Cornelia, Kurthen, Reiner, Schulze-Koops, Hendrik, Schwenke, Holger, Sieburg, Maren, Specker, Christof, Tony, Hans-Peter, Wassenberg, Siegfried, Wendler, Jörg, Caporali, Roberto, Epis, Oscar, Matucci-Cerinic, Marco, Salvarani, Carlo, Dubikov, Alexander, Kamalova, Rimma, Korolev, Maxim, I. Mazurov, Vadim, Puntus, Ekaterina, Damjanov, Nemanja, Ilic, Tatjana, Lazarevic, Milijanka, Milenkovic, Sasa, Petronijevic, Milan, Gabay, Cem, Bouajina, Elyes, Elleuch, Mohamed, Burmester, Gerd R, Buttgereit, Frank, Bernasconi, Corrado, Álvaro-Gracia, Jose M, Castro, Nidia, Dougados, Maxime, van Laar, Jacob M, Nebesky, Jan Michael, Pethoe-Schramm, Attila, Donath, Marc Y, and John, Markus R

Published
2020
Full Text
View/download PDF

12. Häufigkeiten muskuloskelettaler Symptome und Erkrankungen in der bevölkerungsbezogenen NAKO Gesundheitsstudie

Author

Schmidt, Carsten Oliver, Günther, Klaus-Peter, Goronzy, Jens, Albrecht, Katinka, Chenot, Jean-François, Callhoff, Johanna, Richter, Adrian, Kasch, Richard, Ahrens, Wolfgang, Becher, Heiko, Berger, Klaus, Brenner, Hermann, Fischer, Beate, Franzke, Claus-Werner, Hoffmann, Wolfgang, Holleczek, Bernd, Jaeschke, Lina, Jenning, Carsten, Jöckel, Karl-Heinz, Kaaks, Rudolf, Keil, Thomas, Kluttig, Alexander, Krause, Gérard, Kuß, Oliver, Leitzmann, Michael, Lieb, Wolfgang, Linseisen, Jakob, Löffler, Markus, Meinke-Franze, Claudia, Meisinger, Christa, Michels, Karin B., Mikolajczyk, Rafael, Obi, Nadia, Peters, Annette, Pischon, Tobias, Schikowski, Tamara, Schipf, Sabine, Specker, Christof, Völzke, Henry, Wirkner, Kerstin, Zink, Angela, and Sander, Oliver

Published
2020
Full Text
View/download PDF

14. Rhekiss—The German Register for Child Wish and Pregnancies in Inflammatory Rheumatic Diseases.

Author

Strangfeld, Anja, Meissner, Yvette, Weiß, Anja, Rudi, Tatjana, Zink, Angela, Ellmann, Tanja, Filla, Tim, Aries, Peer, Baraliakos, Xenofon, Bungartz, Christina, Glaser, Cornelia, Henes, Jörg, Lorenz, Hanns‐Martin, Schneider, Matthias, Späthling‐Mestekemper, Susanna, Specker, Christof, Richter, Jutta G., and Fischer‐Betz, Rebecca

Abstract

In pharmacoepidemiology, robust data are needed to judge the impact of drug treatment on pregnancy, pregnancy outcomes and breast‐fed infants. As pregnant and breastfeeding women are usually excluded from randomised clinical trials, observational studies are required. One of those data sources are pregnancy registers specifically developed to focus on certain diseases or disease groups. The German Rhekiss register investigates pregnancies in women with chronic inflammatory rheumatic diseases (IRD). Rhekiss is a nationwide, multicentre, longitudinal study, in which women aged 18 years or older with an underlying IRD can be enrolled by a rheumatologist either when planning a pregnancy or in the first half of pregnancy. Data are collected prospectively at regular follow‐up visits. Rheumatologists and patients provide information in a web‐based system before conception (if enrolment was at the time of pregnancy planning), during and after pregnancy. A smartphone app is available for patients. Maternal and clinical information, general laboratory markers, treatment with antirheumatic and other drugs, adverse events, items related to course and outcome of pregnancy and the health of the child are uniformly assessed for all diseases. Individual information on the IRD includes classification criteria, diagnosis‐specific laboratory parameters, clinical parameters and validated instruments to measure disease activity or damage. Furthermore, patient‐reported outcome measures are captured. A total of 2013 individual patients have been enrolled in the register, and data on 1801 completed pregnancies are available. In summary, Rhekiss is a comprehensive and complex register that can answer various research questions about pregnancy in women with chronic IRDs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries.

Author

Hasseli, Rebecca, Hanses, Frank, Stecher, Melanie, Specker, Christof, Weise, Tobias, Borgmann, Stefan, Hasselberger, Martina, Hertenstein, Bernd, Hower, Martin, Hoyer, Bimba F., Koll, Carolin, Krause, Andreas, von Lilienfeld-Toal, Marie, Lorenz, Hanns-Martin, Merle, Uta, Nunes de Miranda, Susana M., Pletz, Mathias W., Regierer, Anne C., Richter, Jutta G., and Rieg, Siegbert

Published
2024
Full Text
View/download PDF

18. Fachspezifische Beurteilung des Berichts der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Darstellung der Versorgungslandschaft im Bereich der Inneren Medizin in Deutschland durch die Deutsche Gesellschaft für Rheumatologie e.V. (DGRh).

Author

Braun, Jürgen, Krause, Andreas, Schulze-Koops, Hendrik, Haase, Isabell, Kötter, Ina, Hoyer, Bimba Franziska, Aringer, Martin, Krusche, Martin, Voormann, Anna Julia, Wagner, Ulf, Schwarting, Andreas, and Specker, Christof

Abstract

Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

20. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

Author

Albrecht, Katinka, Krüger, Klaus, Wollenhaupt, Jürgen, Alten, Rieke, Backhaus, Marina, Baerwald, Christoph, Bolten, Wolfgang, Braun, Jürgen, Burkhardt, Harald, Burmester, Gerd R., Gaubitz, Markus, Gause, Angela, Gromnica-Ihle, Erika, Kellner, Herbert, Kuipers, Jens, Krause, Andreas, Lorenz, Hans-Martin, Manger, Bernhard, Nüßlein, Hubert, Pott, Hans-Georg, Rubbert-Roth, Andrea, Schneider, Matthias, Specker, Christof, Schulze-Koops, Hendrik, Tony, Hans-Peter, Wassenberg, Siegfried, and Müller-Ladner, Ulf

Published
2014
Full Text
View/download PDF

31. Kryoglobulinämische Vaskulitis.

Author

Specker, Christof, Passens, Denise, and Schlaak, Jörg

Abstract

Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

33. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination.

Author

Specker, Christof, Aries, Peer, Braun, Jürgen, Burmester, Gerd, Fischer-Betz, Rebecca, Hasseli, Rebecca, Holle, Julia, Hoyer, Bimba Franziska, Iking-Konert, Christof, Krause, Andreas, Krüger, Klaus, Krusche, Martin, Leipe, Jan, Lorenz, Hanns-Martin, Moosig, Frank, Schmale-Grede, Rotraud, Schneider, Matthias, Strangfeld, Anja, Voll, Reinhard, and Voormann, Anna

Published
2021
Full Text
View/download PDF

37. A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany.

Author

Hasseli, Rebecca, Pfeil, Alexander, Krause, Andreas, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Specker, Christof, for the COVID-19 Task Force of the German Society for Rheumatology (DGRh), Hoyer, Bimba, Lorenz, Hanns-Martin, Regierer, Anne, Richter, Jutta, Schmeiser, Tim, Strangfeld, Anja, Voll, Reinhard, and Voormann, Anna

Subjects
COVID-19 vaccines, RHEUMATOLOGISTS, PHYSICIANS, RHEUMATISM, VACCINE effectiveness
Abstract

The objective is to evaluate the attitude of rheumatologists regarding the use of COVID-19 vaccination in patients with inflammatory rheumatic diseases (IRDs). From February 2nd until March 15th, 2021, rheumatologists from Germany were asked to participate anonymously in a survey addressing their attitude with respect to COVID-19 vaccinations of IRD patients. The survey was completed by 214 participants (107 men, 103 women, 4 unspecified). More than half of the physicians (61%) were working in rheumatologic private practices and 62% had more than 20 years of experience in rheumatology. 90% reported to be at least confidential in handling issues of COVID-19 vaccination and 99% would recommend COVID-19 vaccination for IRD patients. The majority would not recommend to stop or reduce immunomodulatory drugs for vaccination except for rituximab. More than 70% would prefer vaccination with a mRNA vaccine for their IRD patients. This study shows that almost all rheumatologists in Germany support the COVID-19 vaccination for their IRD patients without reducing or terminating the actual immunomodulatory medication to potentially improve the response to the vaccine. This attitude is in accordance with the current recommendations of the German Society of Rheumatology regarding COVID-19 vaccination in IRD patients, and indicates that these have been well accepted and work in everyday clinical practice. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV‑2/COVID‑19-Pandemie einschließlich Empfehlungen zur COVID‑19-Impfung

Author

Specker, Christof, Aries, Peer, Braun, Jürgen, Burmester, Gerd, Fischer-Betz, Rebecca, Hasseli, Rebecca, Holle, Julia, Hoyer, Bimba Franziska, Iking-Konert, Christof, Krause, Andreas, Krüger, Klaus, Krusche, Martin, Leipe, Jan, Lorenz, Hanns-Martin, Moosig, Frank, Schmale-Grede, Rotraud, Schneider, Matthias, Strangfeld, Anja, Voll, Reinhard, and Voormann, Anna

Published
2021
Full Text
View/download PDF

41. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2—methodology, key messages and justifying information.

Author

Schulze-Koops, Hendrik, Krüger, Klaus, Hoyer, Bimba Franziska, Leipe, Jan, Iking-Konert, Christof, Specker, Christof, and Rheumatology, the Commission for Pharmacotherapy and the Board of Directors of the German Society for

Subjects
RHEUMATISM treatment, RHEUMATOLOGY, COVID-19 vaccines, HYGIENE, MEDICAL protocols, IMMUNOLOGICAL adjuvants, IMMUNOSUPPRESSIVE agents, COVID-19 pandemic
Abstract

A few days after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was declared a pandemic, the German Society for Rheumatology (DGRh) compiled the first group of recommendations for the care of patients with inflammatory rheumatic diseases in light of SARS-CoV-2/coronavirus disease 2019 (COVID-19). These first recommendations were based on an expert consensus and were largely non-evidence-based. Now that the first scientific data from registries, cross-sectional studies, case reports and case series are available, the DGRh has developed a timely update. This update is based on a literature search of publications available through 15 June 2020 and addresses preventive measures (such as hygiene measures or vaccinations) and the use of immunomodulatory/immunosuppressive drugs. Driven by the commitment to let patients benefit from these new evidence-based recommendations as quickly as possible, the DGRh published the update in German on its homepage and in the Zeitschrift für Rheumatologie immediately after completion. Here we report the key recommendations to make them available to the international community, provide the scientific methodology used to develop the recommendations, give additional thoughts and advice for the management of patients with rheumatic diseases during the COVID-19 pandemic and discuss our recommendations in the context of other international recommendations. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.

Author

Hasseli, Rebecca, Mueller-Ladner, Ulf, Hoyer, Bimba F., Krause, Andreas, Lorenz, Hanns-Martin, Pfeil, Alexander, Richter, Jutta, Schäfer, Martin, Schmeiser, Tim, Strangfeld, Anja, Schulze-Koops, Hendrik, Voll, Reinhard E., Specker, Christof, and Regierer, Anne Constanze

Published
2021
Full Text
View/download PDF

43. Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie e. V. für die Betreuung von Patienten mit entzündlich rheumatischen Erkrankungen im Rahmen der SARS-CoV-2/COVID-19-Pandemie – Update Juli 2020.

Author

Schulze-Koops, Hendrik, Iking-Konert, Christof, Leipe, Jan, Hoyer, Bimba Franziska, Holle, Julia, Moosig, Frank, Aries, Peer, Burmester, Gerd, Fiehn, Christoph, Krause, Andreas, Lorenz, Hanns-Martin, Schneider, Matthias, Sewerin, Philipp, Voormann, Anna, Wagner, Ulf, Krüger, Klaus, and Specker, Christof

Published
2020
Full Text
View/download PDF

44. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.

Author

Hasseli, Rebecca, Mueller-Ladner, Ulf, Schmeiser, Tim, Hoyer, Bimba F., Krause, Andreas, Lorenz, Hanns-Martin, Regierer, Anne Constanze, Richter, Jutta G., Strangfeld, Anja, Voll, Reinhard E., Pfeil, Alexander, Schulze-Koops, Hendrik, and Specker, Christof

Published
2020
Full Text
View/download PDF

45. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.

Author

Kedor, Claudia, Listing, Joachim, Zernicke, Jan, Weiß, Anja, Behrens, Frank, Blank, Norbert, Henes, Joerg Christoph, Kekow, Joern, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Seipelt, Eva, Specker, Christof, and Feist, Eugen

Subjects
THERAPEUTIC use of monoclonal antibodies, RESEARCH, RESEARCH methodology, EVALUATION research, MEDICAL cooperation, ANTIRHEUMATIC agents, TREATMENT effectiveness, COMPARATIVE studies, RANDOMIZED controlled trials, RHEUMATOID arthritis, BLIND experiment, STATISTICAL sampling
Abstract

Background: Inhibition of interleukin (IL)-1 represents a promising treatment option in adult-onset Still's disease (AOSD).Objective: To investigate the efficacy and safety of canakinumab in patients with AOSD and active joint involvement by means of a multicentre, double-blind, randomised, placebo-controlled trial.Methods: Patients with AOSD and active joint involvement (tender and swollen joint counts of ≥4 each) were treated with canakinumab (4 mg/kg, maximum 300 mg subcutaneous every 4 weeks) or placebo. The primary endpoint was the proportion of patients with a clinically relevant reduction in disease activity at week 12 as determined by the change in disease activity score (ΔDAS28>1.2).Results: At enrolment, patients had high active disease with a mean DAS28(ESR) of 5.4 in the canakinumab and 5.3 in the placebo group, respectively. In the intention-to-treat analysis, 12 patients (67%) in the canakinumab group and 7 patients (41%) in the placebo group fulfilled the primary outcome criterion (p=0.18). In the per-protocol analysis, significantly higher American College of Rheumatology (ACR) 30% (61% vs 20%, p=0.033), ACR 50% (50% vs 6.7%, p=0.009) and ACR 70% (28% vs 0%, p=0.049) response rates were observed in the canakinumab group compared with the placebo group. Two patients in the canakinumab group experienced a serious adverse event.Conclusion: Although the study was terminated prematurely and the primary endpoint was not achieved, treatment with canakinumab led to an improvement of several outcome measures in AOSD. The overall safety findings were consistent with the known profile of canakinumab. Thus, our data support indication for IL-1 inhibition with canakinumab in AOSD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Beeinflusst Methotrexat die Wirksamkeit der Impfung gegen SARS-CoV-2?

Author

Krüger, Klaus, Ad-hoc Kommission Covid-19-Empfehlungen der Deutschen Gesellschaft für Rheumatologie, Burmester, Gerd-Rüdiger, Krusche, Martin, Voormann, Anna Julia, Schmale-Grede, Rotraut, Specker, Christof, Krause, Andreas, Schulze-Koops, Hendrik, Braun, Jürgen, Aries, Peer, Moosig, Frank, Holle, Julia, Schneider, Matthias, Fischer-Betz, Rebecca, Voll, Reinhard, Iking-Konert, Christof, Lorenz, Hanns-Martin, Wagner, Ulf, and Leipe, Jan

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results